9:03 AM ET
8-K
M&A Deal
Nexgel M&A Deal with Fountainhead LifeSciences
NEXGEL announced a strategic recapitalization and update on a potential merger with Fountainhead LifeSciences, including its affiliates Sequence LifeScience and NVISION Biomedical Technologies. As part of the plan, holders of $14.125 million in convertible notes (95% of outstanding principal) agreed to convert their debt into common stock at $5.50 per share, contingent upon the completion of the merger.
- Counterparty
- Fountainhead LifeSciences